Loading clinical trials...
Loading clinical trials...
A Phase 2a, Multicenter, Randomized, Open-Label Study to Assess the Efficacy, Safety, and Tolerability of RBS2418 in Combination With Tremelimumab Plus Durvalumab for Participants With Advanced Unresectable Hepatocellular Carcinoma
Conditions
Interventions
RBS2418
STRIDE (durvalumab + tremelimumab)
Locations
4
United States
Johns Hopkins
Baltimore, Maryland, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
University of Texas Southwestern
Dallas, Texas, United States
START Dallas Fort Worth
Fort Worth, Texas, United States
Start Date
April 10, 2026
Primary Completion Date
April 1, 2027
Completion Date
August 1, 2027
Last Updated
April 24, 2026
Lead Sponsor
Riboscience, LLC.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions